Variant position: 209 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1785 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human MLNVIFTRMENQVLQEAREL EKPIQSKPQSPVIQAAAVSPK
Mouse MLNVIFTRMENQVLQEAREL EKPMQSKPQSPVIQATAGSPK
Rat MLNVIFTRMENQVLQEAREL EKPIQSKPQSPVIQATAGSPK
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 1785 Brefeldin A-inhibited guanine nucleotide-exchange protein 2
2 – 224 DCB; DCB:DCB domain and DCB:HUS domain interaction
214 – 214 Phosphoserine
218 – 218 Phosphoserine
227 – 227 Phosphoserine
Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex.
Sheen V.L.; Ganesh V.S.; Topcu M.; Sebire G.; Bodell A.; Hill R.S.; Grant P.E.; Shugart Y.Y.; Imitola J.; Khoury S.J.; Guerrini R.; Walsh C.A.;
Nat. Genet. 36:69-76(2004)
Cited for: INVOLVEMENT IN PVNH2; VARIANT PVNH2 LYS-209;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.